Loading company…
Spirogen develops biopharmaceutical therapies, with a focus on antibody-drug conjugates for oncology.
Founded in 2000 and based in London, UK, Spirogen develops biopharmaceutical therapies, particularly antibody-drug conjugates for oncology and other areas. MedImmune, Inc. acquired it in October 2013 for USD 200 mn, with potential additional payments of up to USD 240 mn based on developmental milestones. The company reported no revenue in 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in